Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

pharmafocusasiaSeptember 13, 2018

Tag: Opiant Pharmaceuticals , Consort Medical plc , OPNT003

PharmaSources Customer Service